e8vk
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): May 8, 2008
Micrus Endovascular Corporation
(Exact name of registrant as specified in its charter)
000-51323
(Commission File Number)
|
|
|
Delaware
(State or other jurisdiction of incorporation)
|
|
23-2853441
(IRS Employer Identification No.) |
821 Fox Lane
San Jose, CA 95131
(Address of principal executive offices with zip code)
(408) 433-1400
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Item 2.02. Results of Operations and Financial Condition.
On May 8, 2008, Micrus Endovascular Corporation (Micrus) issued a press release reporting
its financial results for the fiscal year ended March 31, 2008. A copy of this earnings release is
attached as Exhibit 99.1 hereto. Following the issuance of this earnings release, Micrus hosted an
earnings call in which its financial results for the fiscal year ended March 31, 2008 were
discussed.
Exhibit 99.1 contains forward-looking statements within the meaning of the federal securities
laws. These statements are present expectations, and are subject to the limitations listed therein
and in Micrus other SEC reports, including that actual events or results may differ materially
from those in the forward-looking statements.
The foregoing information (including the exhibit hereto) is being furnished under Item 2.02
Results of Operations and Financial Condition and shall not be deemed filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as amended, except as shall be
expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
Exhibit |
|
Description |
99.1
|
|
Press Release dated May 8, 2008. |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
MICRUS ENDOVASCULAR CORPORATION
(Registrant)
|
|
Date: May 8, 2008 |
By: |
/s/ Gordon T. Sangster
|
|
|
|
Gordon T. Sangster |
|
|
|
Chief Financial Officer |
|
EXHIBIT INDEX
|
|
|
Exhibit |
|
Description |
99.1
|
|
Press Release dated May 8, 2008 |